Offstream
news

---

Changes

1. The Canadian government signs an agreement with AstraZeneca to procure 100,000 doses of a COVID-19 antibody therapy Evushield for high-risk patients.
   2022-02-24 03:06:05 (First version)
2. The Canadian government signs an agreement with AstraZeneca to procure 100,000 doses of the Evushield COVID-19 antibody therapy for use in high-risk patients.
   (Current version)

---

Related

The North Kivu province in the Democratic Republic of the Congo will begin its COVID-19 vaccination campaign, with around 60,000 doses arriving in Goma. This comes after the country's announcement that it will kick off uts own vaccination campaign by using AstraZeneca's vaccine.
2021-04-22

Nicaragua says that they have slowly started vaccinations for people over 60 using an AstraZeneca vaccine that was made in India.
2021-04-8

The Haiti government rejects an offer from the World Health Organization to receive 756,000 doses of the vaccine produced by AstraZeneca.
2021-04-6

AstraZeneca announces that the efficacy rating of its COVID-19 vaccine candidate has been lowered to 76%, following new analyses of the trial run in the United States. Earlier in the week, the company had been criticized for advertising its vaccine with a 79% efficacy rating using what critics claimed was outdated data.
2021-03-25

Ukraine secures 12 million doses of the vaccine developed by AstraZeneca and Novavax.
2021-02-5

Brazil begins distribution of the AstraZeneca-Oxford University vaccine.
2021-01-23

The Brazilian Health Regulatory Agency (Anvisa) grants emergency use authorization requests for the vaccines developed by Sinovac and Oxford-AstraZeneca.
2021-01-17

Malaysia signs a deal to receive 6.4 million doses of the AstraZeneca vaccine.
2020-12-22

The Indian government announces that the country will speed up their reviews of vaccines developed by Pfizer and AstraZeneca.
2020-12-7

Prime Minister Scott Morrison announces that his country has signed a deal with the British-Swedish pharmaceutical company AstraZeneca to manufacture a vaccine against COVID-19 that the company is developing with the Oxford Vaccine Group. The vaccine is currently in Phase III efficacy trials and AstraZeneca says it is targeting a formulation of results by the end of the year. Morrison states that the deal also allows citizens to receive immediate and free access to the vaccines, if successful.
2020-08-18